As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

Boehringer Ingelheim halts Iclepertin trials after failure to show efficacy Boehringer Ingelheim stops research on Iclepertin ...

The company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...

Boehringer healthcare HCP Illustrative image Boehringer Ingelheim today announced top-line results from the Phase III CONNEX ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

HHS told the Second Circuit that Boehringer Ingelheim’s voluntary participation in Medicare negotiations “undermines” its ...

Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...

Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on ...